✦ LIBER ✦

Evaluation of pirarubicin–cisplatin chemotherapy in the treatment for refractory and recurrent high-grade osteosarcoma: experience of a single institute

✍ Scribed by Wei-Xiang Qi, Ai-Na He, Li-Na Tang, Zan Shen, Yang Yao

Book ID: 118821417
Publisher: Springer US
Year: 2011
Tongue: English
Weight: 167 KB
Volume: 29
Category: Article
ISSN: 1357-0560
DOI: 10.1007/s12032-011-0021-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of pirarubicin-based versus g

Comparison of pirarubicin-based versus gemcitabine–docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience

✍ Aina He, Weixiang Qi, Yujing Huang, Yuanjue Sun, Zan Shen, Hui Zhao, Yumei Yang, 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 283 KB

Irinotecan hydrochloride for the treatme

Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma : A single institution experience

✍ Katsuki Sugiyama; Ken Omachi; Keiichi Fujiwara; Takashi Saotome; Nobuyuki Mizunu 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB

## Abstract ## BACKGROUND Irinotecan hydrochloride (CPT‐11) has a broad range of antitumor activity and has demonstrated little cross‐resistance with doxorubicin or vincristine. In the current study, the authors investigated the efficacy and adverse effects of irinotecan in the treatment of recurr

Comparison of the efficacy between pacli

Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: A single institution experience

✍ Hee Seung Kim; Jae Weon Kim; Hong Gyun Wu; Hyun Hoon Chung; Noh Hyun Park; Yong 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 324 KB

53 POSTER A phase II, multicenter, rando

53 POSTER A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin®) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva®) compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer

✍ R. Herbst; V. O'Neill; L. Fehrenbacher; C. Belani; P. Bonomi; L. Hart; O. Melnyk 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB